Aquestive Therapeutics, Inc. (AQST)

NASDAQ: AQST · Real-Time Price · USD

3.910

+0.340 (9.52%)

At close: Nov 13, 2026, 4:00 PM EST

3.920

+0.010 (0.26%)

After-hours: Nov 13, 2026, 7:59 PM EST

Aquestive Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	48.84	44.55	57.56	50.58	47.68	50.83
Revenue Growth	12.53%	-22.61%	13.79%	6.09%	-6.20%	10.87%
Cost of Revenue	16.93	18.56	17.87	20.83	19.39	14.99
Gross Profit	31.91	25.99	39.69	29.75	28.29	35.84
Selling, General & Admin	72.03	79.85	50.18	31.75	52.88	53.48
Research & Development	15.61	17.19	20.28	13.1	17.48	17.05
Operating Expenses	87.64	97.04	70.46	44.85	70.36	70.52
Operating Income	-55.74	-71.05	-30.77	-15.1	-42.07	-34.68
Interest Expense	-14.93	-17.1	-16.82	-7.46	-12.44	-22.46
Interest & Investment Income	3.07	4.37	3.14	1.82	0.1	0.42
Other Non Operating Income (Expenses)	-	-	-	6	-	-
EBT Excluding Unusual Items	-67.59	-83.78	-44.45	-14.74	-54.41	-56.72
Legal Settlements	-	-	-	8.5	-	-
Other Unusual Items	-11.68	-	0.3	-1.38	-	-13.82
Pretax Income	-79.28	-83.78	-44.15	-7.63	-54.41	-70.54
Income Tax Expense	-	-	-0.01	0.25	-	-
Net Income	-79.28	-83.78	-44.14	-7.87	-54.41	-70.54
Net Income to Common	-79.28	-83.78	-44.14	-7.87	-54.41	-70.54
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	124	107	87	61	49	38
Shares Outstanding (Diluted)	124	107	87	61	49	38
Shares Change	24.83%	23.29%	41.58%	25.69%	27.99%	13.15%
EPS (Basic)	-0.64	-0.78	-0.51	-0.13	-1.12	-1.85
EPS (Diluted)	-0.64	-0.78	-0.51	-0.13	-1.12	-1.85
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-40.7	-52.99	-35.92	-7.38	-10.84	-33.89
Free Cash Flow Per Share	-0.33	-0.50	-0.41	-0.12	-0.22	-0.89
Gross Margin	65.34%	58.34%	68.95%	58.82%	59.34%	70.51%
Operating Margin	-114.13%	-159.50%	-53.46%	-29.86%	-88.23%	-68.22%
Profit Margin	-162.33%	-188.09%	-76.68%	-15.56%	-114.12%	-138.77%
Free Cash Flow Margin	-83.33%	-118.97%	-62.40%	-14.58%	-22.74%	-66.67%
EBITDA	-55.17	-70.48	-30.03	-13.73	-39.51	-31.53
EBITDA Margin	-112.98%	-158.22%	-52.17%	-27.14%	-82.87%	-62.02%
D&A For EBITDA	0.56	0.57	0.74	1.37	2.55	3.15
EBIT	-55.74	-71.05	-30.77	-15.1	-42.07	-34.68
EBIT Margin	-114.12%	-159.50%	-53.46%	-29.86%	-88.23%	-68.22%

SEC Filings: 10-K · 10-Q